Trial · NCT01170117

Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

NCT01170117, Not applicable, Completed, New York State Psychiatric Institute; results first posted 2017-08-25

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa. Trials, record NCT01170117. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01170117

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa
NCT number: NCT01170117
Status: Completed
Phases: Not applicable
Enrollment: 152 participants, actual
Lead sponsor: New York State Psychiatric Institute
Conditions: Anorexia Nervosa
Interventions: Olanzapine, Placebo
First posted: 2010-07-27
Last updated: 2018-06-29
Results first posted: 2017-08-25

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Rate of Weight Change	Weekly during 16-week trial and twice during 8 weeks follow-up	Comparison of rate of weight change between patients receiving olanzapine and those receiving placebo
Primary	Psychological Change	Weekly during 16-week intervention and twice during 8-week follow-up	Comparison of psychological change as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS), in patients receiving olanzapine compared with those receiving placebo. The Y-BOCS is divided into two sections: obsessive and compulsive. The scores for each section range from 1 to 20. The overall scores are obtained from adding scores for the two sections, to obtain a range between 2-40. A lower score reflects improvement/ fewer obsessive compulsive symptoms. A score of 25 or more is considered moderately severe, a score of 30 or more is considered severe, and a score of more than 35 is considered very severe.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Rate of Weight Change	Weekly during 16-week trial and twice during 8 weeks follow-up	Patients assigned to receive placebo or olanzapine for 16 weeks.	kg/m^2 per month	MEAN
PRIMARY	Psychological Change	Weekly during 16-week intervention and twice during 8-week follow-up		YBOCs score units per month	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Rate of Weight Change	Placebo	0.095	Standard Error 0.053	kg/m^2 per month
Rate of Weight Change	Olanzapine	0.260	Standard Error 0.051	kg/m^2 per month
Psychological Change	Placebo	0.762	Standard Deviation 0.375	YBOCs score units per month
Psychological Change	Olanzapine	0.800	Standard Deviation 0.350	YBOCs score units per month

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	77
Overall Study	STARTED	Olanzapine	75
Overall Study	COMPLETED	Placebo	47
Overall Study	COMPLETED	Olanzapine	55
Overall Study	NOT COMPLETED	Placebo	30
Overall Study	NOT COMPLETED	Olanzapine	20

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Mild undulating movement in his posterior tongue on the Abnormal Involuntary Movement Scale	Musculoskeletal and connective tissue disorders	Placebo	0	77	0
other	Mild undulating movement in his posterior tongue on the Abnormal Involuntary Movement Scale	Musculoskeletal and connective tissue disorders	Olanzapine	1	75	1
other	Rash	Skin and subcutaneous tissue disorders	Placebo	0	77	0
other	Rash	Skin and subcutaneous tissue disorders	Olanzapine	1	75	1
serious	Patient hospitalized in eating disorder center to pursue higher level of care.	Psychiatric disorders	Placebo	7	77	7
serious	Patient hospitalized in eating disorder center to pursue higher level of care.	Psychiatric disorders	Olanzapine	11	75	11
serious	Overdose	Injury, poisoning and procedural complications	Placebo	0	77	0
serious	Overdose	Injury, poisoning and procedural complications	Olanzapine	2	75	2
serious	Abnormal EKG	Cardiac disorders	Placebo	1	77	1
serious	Abnormal EKG	Cardiac disorders	Olanzapine	1	75	1

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Placebo	0	77
Total, all-cause mortality	Olanzapine	0	75
Total, other adverse events	Placebo	0	77
Total, other adverse events	Olanzapine	2	75
Total, serious adverse events	Placebo	13	77
Total, serious adverse events	Olanzapine	16	75

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
18558642	BACKGROUND	PubMed
30654643	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01MH085921	Olanzapine Versus Placebo in Outpatients with Anorexia Nervosa	ATTIA, EVELYN	NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC	NATIONAL INSTITUTE OF MENTAL HEALTH	2010 to 2014

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Olanzapine vs Placebo: deaths from any cause	Trial comparisons
Olanzapine vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01170117

GET https://conductscience.org/api/trials/v1/NCT01170117/registered

API reference For AI assistants